BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Evans CT, Safdar N. Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection. Clin Infect Dis. 2015;60 Suppl 2:S66-S71. [PMID: 25922403 DOI: 10.1093/cid/civ140] [Cited by in Crossref: 160] [Cited by in F6Publishing: 143] [Article Influence: 26.7] [Reference Citation Analysis]
Number Citing Articles
1 Xu C, Wang D, Huber A, Weese S, Warriner K. Persistence of Clostridium difficile in wastewater treatment-derived biosolids during land application or windrow composting. J Appl Microbiol 2016;120:312-20. [DOI: 10.1111/jam.13018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
2 Josephs-Spaulding J, Beeler E, Singh OV. Human microbiome versus food-borne pathogens: friend or foe. Appl Microbiol Biotechnol 2016;100:4845-63. [PMID: 27102132 DOI: 10.1007/s00253-016-7523-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Leeds JA. Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571. Cold Spring Harb Perspect Med 2016;6:a025445. [PMID: 26834162 DOI: 10.1101/cshperspect.a025445] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Hematyar Y, Pirzadeh T, Moaddab SR, Ahangarzadeh Rezaee M, Memar MY, Samadi Kafil H. Clostridium difficile in patients with nosocomial diarrhea, Northwest of Iran. Health Promot Perspect 2020;10:148-51. [PMID: 32296628 DOI: 10.34172/hpp.2020.24] [Reference Citation Analysis]
5 Muñoz M, Camargo M, Ríos-Chaparro DI, Gómez P, Patarroyo MA, Ramírez JD. Community-acquired infection with hypervirulent Clostridium difficile isolates that carry different toxin and antibiotic resistance loci: a case report. Gut Pathog 2017;9:63. [PMID: 29151897 DOI: 10.1186/s13099-017-0212-y] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Wenzler E, Mulugeta SG, Danziger LH. The Antimicrobial Stewardship Approach to Combating Clostridium Difficile. Antibiotics (Basel) 2015;4:198-215. [PMID: 27025621 DOI: 10.3390/antibiotics4020198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
7 Koon HW, Su B, Xu C, Mussatto CC, Tran DH, Lee EC, Ortiz C, Wang J, Lee JE, Ho S, Chen X, Kelly CP, Pothoulakis C. Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters. Am J Physiol Gastrointest Liver Physiol. 2016;311:G610-G623. [PMID: 27514478 DOI: 10.1152/ajpgi.00150.2016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
8 Harris AD, Sbarra AN, Leekha S, Jackson SS, Johnson JK, Pineles L, Thom KA. Electronically Available Comorbid Conditions for Risk Prediction of Healthcare-Associated Clostridium difficile Infection. Infect Control Hosp Epidemiol 2018;39:297-301. [PMID: 29397800 DOI: 10.1017/ice.2018.10] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
9 Slain D, Georgulis A, Dermitt R, Morris L, Colodny SM. Impact of an automatic hospital probiotic protocol on Clostridioides (Clostridium) difficile infection (CDI) rates and CDI antibiotic usage in a community hospital setting. J Infect Prev 2020;21:72-5. [PMID: 33425020 DOI: 10.1177/1757177419892309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Ouwehand AC, Forssten S, Hibberd AA, Lyra A, Stahl B. Probiotic approach to prevent antibiotic resistance. Ann Med 2016;48:246-55. [PMID: 27092975 DOI: 10.3109/07853890.2016.1161232] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
11 Rodriguez C, Fernandez J, Van Broeck J, Taminiau B, Avesani V, Boga JA, Vazquez F, Delmée M, Daube G. Clostridium difficile presence in Spanish and Belgian hospitals. Microb Pathog 2016;100:141-8. [PMID: 27616443 DOI: 10.1016/j.micpath.2016.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
12 Murray B, Wolfe C, Marra A, Pillar C, Shinabarger D. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile. J Antimicrob Chemother 2020;75:2149-55. [PMID: 32285102 DOI: 10.1093/jac/dkaa134] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Scott RD 2nd, Slayton RB, Lessa FC, Baggs J, Culler SD, McDonald LC, Jernigan JA. Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent Clostridioides difficile infection in US hospitals. Antimicrob Resist Infect Control 2019;8:17. [PMID: 30680153 DOI: 10.1186/s13756-018-0459-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Popoff MR. Clostridium difficile and Clostridium sordellii toxins, proinflammatory versus anti-inflammatory response. Toxicon 2018;149:54-64. [DOI: 10.1016/j.toxicon.2017.11.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
15 Pai S, Polgreen PM, Segre AM, Sewell DK, Pemmaraju SV; CDC MInD-Healthcare group. Spatiotemporal clustering of in-hospital Clostridioides difficile infection. Infect Control Hosp Epidemiol 2020;41:418-24. [PMID: 32000873 DOI: 10.1017/ice.2019.350] [Reference Citation Analysis]
16 Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. Am J Health Syst Pharm 2019;76:581-90. [PMID: 31361830 DOI: 10.1093/ajhp/zxz032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
17 Jose S, Mukherjee A, Horrigan O, Setchell KDR, Zhang W, Moreno-Fernandez ME, Andersen H, Sharma D, Haslam DB, Divanovic S, Madan R. Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice. Mucosal Immunol 2021;14:500-10. [PMID: 32811993 DOI: 10.1038/s41385-020-00338-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ford DC, Schroeder MC, Ince D, Ernst EJ. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients. American Journal of Health-System Pharmacy 2018;75:1110-21. [DOI: 10.2146/ajhp170554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 McFarland LV. Primary prevention of Clostridium difficile infections - how difficult can it be? Expert Rev Gastroenterol Hepatol 2017;11:507-21. [PMID: 28347160 DOI: 10.1080/17474124.2017.1312343] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
20 Garneau JR, Sekulovic O, Dupuy B, Soutourina O, Monot M, Fortier LC. High Prevalence and Genetic Diversity of Large phiCD211 (phiCDIF1296T)-Like Prophages in Clostridioides difficile. Appl Environ Microbiol 2018;84:e02164-17. [PMID: 29150513 DOI: 10.1128/AEM.02164-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
21 Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One 2018;13:e0209205. [PMID: 30586435 DOI: 10.1371/journal.pone.0209205] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
22 Zhao C, Guo S, Jia X, Xu X. Distribution and risk factor analysis for Clostridium difficile-associated diarrhea among hospitalized children over one year of age. Pediatr Investig 2020;4:37-42. [PMID: 32851340 DOI: 10.1002/ped4.12155] [Reference Citation Analysis]
23 Calderón-Romero P, Castro-Córdova P, Reyes-Ramírez R, Milano-Céspedes M, Guerrero-Araya E, Pizarro-Guajardo M, Olguín-Araneda V, Gil F, Paredes-Sabja D. Clostridium difficile exosporium cysteine-rich proteins are essential for the morphogenesis of the exosporium layer, spore resistance, and affect C. difficile pathogenesis. PLoS Pathog 2018;14:e1007199. [PMID: 30089172 DOI: 10.1371/journal.ppat.1007199] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
24 Kachlíková M, Sabaka P, Koščálová A, Bendžala M, Dovalová Z, Stankovič I. Comorbid status and the faecal microbial transplantation failure in treatment of recurrent Clostridioides difficile infection - pilot prospective observational cohort study. BMC Infect Dis 2020;20:52. [PMID: 31948404 DOI: 10.1186/s12879-020-4773-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Roncarati G, Dallolio L, Leoni E, Panico M, Zanni A, Farruggia P. Surveillance of Clostridium difficile Infections: Results from a Six-Year Retrospective Study in Nine Hospitals of a North Italian Local Health Authority. Int J Environ Res Public Health 2017;14:E61. [PMID: 28075419 DOI: 10.3390/ijerph14010061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
26 Maisa A, Ross G, Verlander NQ, Fairley D, Bradley DT, Patterson L. Comparing the epidemiology of community- and hospital-associated Clostridium difficile infections in Northern Ireland, 2012-2016: a population data linkage and case-case study. Epidemiol Infect 2019;147:e141. [PMID: 30869054 DOI: 10.1017/S0950268819000414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Xuan S, Zangwill KM, Ni W, Ma J, Hay JW. Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection. J Gen Intern Med 2020;35:1102-10. [PMID: 32016703 DOI: 10.1007/s11606-019-05487-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Granata G, Petrosillo N, Adamoli L, Bartoletti M, Bartoloni A, Basile G, Bassetti M, Bonfanti P, Borromeo R, Ceccarelli G, De Luca AM, Di Bella S, Fossati S, Franceschini E, Gentile I, Giacobbe DR, Giacometti E, Ingrassia F, Lagi F, Lobreglio G, Lombardi A, Lupo LI, Luzzati R, Maraolo AE, Mikulska M, Mondelli MU, Mularoni A, Mussini C, Oliva A, Pandolfo A, Rogati C, Trapani FF, Venditti M, Viale P, Caraffa E, Cataldo MA, On Behalf Of The ReCloDi Recurrence Of Clostridioides Difficile Infection Study Group. Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections. J Clin Med 2021;10:1127. [PMID: 33800334 DOI: 10.3390/jcm10051127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Deshpande A, Pant C, Olyaee M, Donskey CJ. Hospital readmissions related to Clostridium difficile infection in the United States. Am J Infect Control 2018;46:346-7. [PMID: 29050906 DOI: 10.1016/j.ajic.2017.08.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
30 Banawas SS. Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. Biomed Res Int 2018;2018:8414257. [PMID: 29682562 DOI: 10.1155/2018/8414257] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
31 Katzer KC, Hagel S, Reuken PA, Bruns T, Stallmach A. Development and validation of a simple and robust model to predict 30-day mortality in patients with Clostridioides difficile-associated enterocolitis. BMJ Open Gastroenterol 2020;7:e000468. [PMID: 32912845 DOI: 10.1136/bmjgast-2020-000468] [Reference Citation Analysis]
32 Reeves JS, Evans ME, Simbartl LA, Kralovic SM, Kelly AA, Jain R, Roselle GA. Clostridium difficile Infections in Veterans Health Administration Long-Term Care Facilities. Infect Control Hosp Epidemiol 2016;37:295-300. [PMID: 26686361 DOI: 10.1017/ice.2015.309] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
33 Mora-Uribe P, Miranda-Cárdenas C, Castro-Córdova P, Gil F, Calderón I, Fuentes JA, Rodas PI, Banawas S, Sarker MR, Paredes-Sabja D. Characterization of the Adherence of Clostridium difficile Spores: The Integrity of the Outermost Layer Affects Adherence Properties of Spores of the Epidemic Strain R20291 to Components of the Intestinal Mucosa. Front Cell Infect Microbiol 2016;6:99. [PMID: 27713865 DOI: 10.3389/fcimb.2016.00099] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
34 Hudspeth WB, Qeadan F, Phipps EC. Disparities in the incidence of community-acquired Clostridioides difficile infection: An area-based assessment of the role of social determinants in Bernalillo County, New Mexico. American Journal of Infection Control 2019;47:773-9. [DOI: 10.1016/j.ajic.2018.12.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Allard FD, Stelow EB. Review of Drug-induced Injury in Mucosal Biopsies From the Tubular Gastrointestinal Tract. Advances in Anatomic Pathology 2019;26:151-70. [DOI: 10.1097/pap.0000000000000230] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Sewell DK, Simmering JE, Justice S, Pemmaraju SV, Segre AM, Polgreen PM. Estimating the Attributable Disease Burden and Effects of Interhospital Patient Sharing on Clostridium difficile Infections. Infect Control Hosp Epidemiol 2019;40:656-61. [DOI: 10.1017/ice.2019.73] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
37 Gil F, Paredes-sabja D. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections. Future Microbiology 2016;11:1179-89. [DOI: 10.2217/fmb-2016-0064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
38 Shelby RD, Janzow GE, Mashburn-Warren L, Galley J, Tengberg N, Navarro J, Conces M, Bailey MT, Goodman SD, Besner GE. A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis. Gut Microbes 2020;12:1814119. [PMID: 32954922 DOI: 10.1080/19490976.2020.1814119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Joyce NR, Mylonakis E, Mor V. Effect of Clostridium difficile Prevalence in Hospitals and Nursing Homes on Risk of Infection. J Am Geriatr Soc 2017;65:1527-34. [PMID: 28394408 DOI: 10.1111/jgs.14838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
40 Cançado GGL, Silva ROS, Nader AP, Lobato FCF, Vilela EG. Impact of simultaneous glutamate dehydrogenase and toxin A/B rapid immunoassay on Clostridium difficile diagnosis and treatment in hospitalized patients with antibiotic-associated diarrhea in a university hospital of Brazil: Impact of CDI diagnosis on treatment rates. Journal of Gastroenterology and Hepatology 2018;33:393-6. [DOI: 10.1111/jgh.13901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
41 Costa CL, Mano de Carvalho CB, González RH, Gifoni MAC, Ribeiro RA, Quesada-Gómez C, Brito GAC. Molecular epidemiology of Clostridium difficile infection in a Brazilian cancer hospital. Anaerobe 2017;48:232-6. [PMID: 28987390 DOI: 10.1016/j.anaerobe.2017.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
42 Charlton T, Kovacs-simon A, Michell S, Fairweather N, Tate E. Quantitative Lipoproteomics in Clostridium difficile Reveals a Role for Lipoproteins in Sporulation. Chemistry & Biology 2015;22:1562-73. [DOI: 10.1016/j.chembiol.2015.10.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
43 Caupenne A, Ingrand P, Ingrand I, Forestier E, Roubaud-Baudron C, Gavazzi G, Paccalin M. Acute Clostridioides difficile Infection in Hospitalized Persons Aged 75 and Older: 30-Day Prognosis and Risk Factors for Mortality. J Am Med Dir Assoc 2020;21:110-4. [PMID: 31537480 DOI: 10.1016/j.jamda.2019.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 de Jager P, Smith O, Bolon S, Thomas J, Richards GA. Epidemiology of Clostridioides difficile in South Africa. PLoS One 2021;16:e0259771. [PMID: 34813626 DOI: 10.1371/journal.pone.0259771] [Reference Citation Analysis]
45 Xu C, Salsali H, Weese S, Warriner K. Inactivation of Clostridium difficile in sewage sludge by anaerobic thermophilic digestion. Can J Microbiol 2016;62:16-23. [PMID: 26564276 DOI: 10.1139/cjm-2015-0511] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
46 Bishop PA, Isache C, McCarter YS, Smotherman C, Gautam S, Jankowski CA. Clinical impact of a pharmacist-led antimicrobial stewardship initiative evaluating patients with Clostridioides difficile colitis. J Investig Med 2020;68:888-92. [PMID: 32066570 DOI: 10.1136/jim-2019-001173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Cohen CC, Dick AW, Agarwal M, Gracner T, Mitchell S, Stone PW. Trends in antibiotics use among long-term US nursing-home residents. Infect Control Hosp Epidemiol 2021;42:311-7. [PMID: 32935657 DOI: 10.1017/ice.2020.422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Theophilou ES, Vohra P, Gallagher MP, Poxton IR, Blakely GW. Generation of Markerless Deletions in the Nosocomial Pathogen Clostridium difficile by Induction of DNA Double-Strand Breaks. Appl Environ Microbiol 2019;85:e02055-18. [PMID: 30478235 DOI: 10.1128/AEM.02055-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Cabral SM, Goodman KE, Blanco N, Leekha S, Magder LS, Nadimpalli G, Pineles L, Thom KA, Harris AD. Comorbidity and severity-of-illness risk adjustment for hospital-onset Clostridioides difficile infection using data from the electronic medical record. Infect Control Hosp Epidemiol 2021;42:955-61. [PMID: 33327970 DOI: 10.1017/ice.2020.1344] [Reference Citation Analysis]
50 Vega L, Herrera G, Muñoz M, Patarroyo MA, Ramírez JD. Occurrence of Blastocystis in Patients with Clostridioides difficile Infection. Pathogens 2020;9:E283. [PMID: 32295242 DOI: 10.3390/pathogens9040283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Yamaguchi T, Konishi H, Aoki K, Ishii Y, Chono K, Tateda K. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. J Infect Chemother 2020;26:483-91. [PMID: 32165071 DOI: 10.1016/j.jiac.2019.12.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
52 Anwar S, Bryan D, Rigsby P, Dougall T, Rijpkema S. Development and verification of an enzyme-linked immunosorbent assay for the quantification of toxoid A and toxoid B from Clostridioides difficile. J Immunol Methods 2021;488:112917. [PMID: 33221460 DOI: 10.1016/j.jim.2020.112917] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Leelahavanichkul A, Panpetch W, Worasilchai N, Somparn P, Chancharoenthana W, Nilgate S, Finkelman M, Chindamporn A, Tumwasorn S. Evaluation of gastrointestinal leakage using serum (1→3)-β-D-glucan in a Clostridium difficile murine model. FEMS Microbiol Lett 2016;363:fnw204. [PMID: 27573235 DOI: 10.1093/femsle/fnw204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
54 Aronoff DM. Building a Better Crystal Ball for Predicting Complications of Clostridium difficile Infection. Clin Infect Dis 2015;61:1789-91. [PMID: 26338793 DOI: 10.1093/cid/civ751] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Alicino C, Giacobbe DR, Durando P, Bellina D, DI Bella AM, Paganino C, Del Bono V, Viscoli C, Icardi G, Orsi A. Increasing incidence of Clostridium difficile infections: results from a 5-year retrospective study in a large teaching hospital in the Italian region with the oldest population. Epidemiol Infect 2016;144:2517-26. [PMID: 27193828 DOI: 10.1017/S0950268816000935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
56 Yun JH, Park GE, Ki HK. Correlation between antibiotic consumption and the incidence of healthcare facility-onset Clostridioides difficile infection: a retrospective chart review and analysis. Antimicrob Resist Infect Control 2021;10:117. [PMID: 34362442 DOI: 10.1186/s13756-021-00986-9] [Reference Citation Analysis]
57 Wang L, Cao J, Li C, Zhang L. IL-27/IL-27 Receptor Signaling Provides Protection in Clostridium difficile-Induced Colitis. The Journal of Infectious Diseases 2018;217:198-207. [DOI: 10.1093/infdis/jix581] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
58 Vitucci JC, Pulse M, Tabor-Simecka L, Simecka J. Epidemic ribotypes of Clostridium (now Clostridioides) difficile are likely to be more virulent than non-epidemic ribotypes in animal models. BMC Microbiol 2020;20:27. [PMID: 32024477 DOI: 10.1186/s12866-020-1710-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Maseda D, Zackular JP, Trindade B, Kirk L, Roxas JL, Rogers LM, Washington MK, Du L, Koyama T, Viswanathan VK, Vedantam G, Schloss PD, Crofford LJ, Skaar EP, Aronoff DM. Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response. mBio 2019;10:e02282-18. [PMID: 30622186 DOI: 10.1128/mBio.02282-18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
60 Anderson PA, Bernatz J, Safdar N. Clostridium difficile Infection: An Orthopaedic Surgeon's Guide to Epidemiology, Management, and Prevention. J Am Acad Orthop Surg 2017;25:214-23. [PMID: 28134674 DOI: 10.5435/JAAOS-D-15-00470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
61 Chiang HY, Huang HC, Chung CW, Yeh YC, Chen YC, Tien N, Lin HS, Ho MW, Kuo CC. Risk prediction for 30-day mortality among patients with Clostridium difficile infections: a retrospective cohort study. Antimicrob Resist Infect Control 2019;8:175. [PMID: 31749963 DOI: 10.1186/s13756-019-0642-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Granata G, Mariotti D, Ascenzi P, Petrosillo N, di Masi A. High Serum Levels of Toxin A Correlate with Disease Severity in Patients with Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:1093. [PMID: 34572675 DOI: 10.3390/antibiotics10091093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Petrosillo N, Granata G, Cataldo MA. Novel Antimicrobials for the Treatment of Clostridium difficile Infection. Front Med (Lausanne) 2018;5:96. [PMID: 29713630 DOI: 10.3389/fmed.2018.00096] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
64 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
65 Chowdhry M, Haden D, Kemper S, Helmick K, Kawsara M, Huggett A, Stark A, Khan A, Shah M, Bhaty M, Farooq J, Singh S, McJunkin B. Usual opioid dosing does not adversely affect the course of healthcare-associated Clostridioides difficile infection. Pain Manag 2021;11:151-7. [PMID: 33350354 DOI: 10.2217/pmt-2020-0066] [Reference Citation Analysis]
66 Chilton C, Pickering D, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clinical Microbiology and Infection 2018;24:476-82. [DOI: 10.1016/j.cmi.2017.11.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
67 Wilcox MH, Chalmers JD, Nord CE, Freeman J, Bouza E. Role of cephalosporins in the era of Clostridium difficile infection. J Antimicrob Chemother 2017;72:1-18. [PMID: 27659735 DOI: 10.1093/jac/dkw385] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
68 Wijarnpreecha K, Sornprom S, Thongprayoon C, Phatharacharukul P, Cheungpasitporn W. Nasogastric tube and outcomes of Clostridium difficile infection: A systematic review and meta-analysis. J Evid Based Med 2018;11:40-5. [PMID: 29322624 DOI: 10.1111/jebm.12288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Shen NT, Leff JA, Schneider Y, Crawford CV, Maw A, Bosworth B, Simon MS. Cost-Effectiveness Analysis of Probiotic Use to Prevent Clostridium difficile Infection in Hospitalized Adults Receiving Antibiotics. Open Forum Infect Dis 2017;4:ofx148. [PMID: 29230429 DOI: 10.1093/ofid/ofx148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
70 Squellati R. Evidence-Based Practice in the Treatment for Antibiotic-Associated Diarrhea in the Intensive Care Unit. Crit Care Nurs Clin North Am 2018;30:87-99. [PMID: 29413218 DOI: 10.1016/j.cnc.2017.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
71 Church DL. Selected Topics in Anaerobic Bacteriology. Microbiol Spectr 2016;4. [PMID: 27726792 DOI: 10.1128/microbiolspec.DMIH2-0015-2015] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Gomceli U, Vangala S, Zeana C, Kelly PJ, Singh M. An Unusual Case of Ototoxicity with Use of Oral Vancomycin. Case Rep Infect Dis 2018;2018:2980913. [PMID: 30057833 DOI: 10.1155/2018/2980913] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
73 Zhou H, Xu Q, Liu Y, Guo LT. Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy. World J Clin Cases 2020; 8(10): 1908-1915 [PMID: 32518780 DOI: 10.12998/wjcc.v8.i10.1908] [Cited by in CrossRef: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Kruger AJ, Durkin C, Mumtaz K, Hinton A, Krishna SG. Early Readmission Predicts Increased Mortality in Cirrhosis Patients After Clostridium difficile Infection. J Clin Gastroenterol 2019;53:e322-7. [PMID: 30045168 DOI: 10.1097/MCG.0000000000001090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
75 Castro-Córdova P, Mendoza-León MJ, Paredes-Sabja D. Using a ligate intestinal loop mouse model to investigate Clostridioides difficile adherence to the intestinal mucosa in aged mice. PLoS One 2021;16:e0261081. [PMID: 34936648 DOI: 10.1371/journal.pone.0261081] [Reference Citation Analysis]
76 Panpetch W, Somboonna N, Palasuk M, Hiengrach P, Finkelman M, Tumwasorn S, Leelahavanichkul A. Oral Candida administration in a Clostridium difficile mouse model worsens disease severity but is attenuated by Bifidobacterium. PLoS One 2019;14:e0210798. [PMID: 30645630 DOI: 10.1371/journal.pone.0210798] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
77 Pizarro-Guajardo M, Díaz-González F, Álvarez-Lobos M, Paredes-Sabja D. Characterization of Chicken IgY Specific to Clostridium difficile R20291 Spores and the Effect of Oral Administration in Mouse Models of Initiation and Recurrent Disease. Front Cell Infect Microbiol 2017;7:365. [PMID: 28856119 DOI: 10.3389/fcimb.2017.00365] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
78 Lee E, Song KH, Bae JY, Yoon D, Hwang JH, Choe PG, Park WB, Bang JH, Kim ES, Park SW, Kim NJ, Oh MD, Kim HB. Risk factors for poor outcome in community-onset Clostridium difficile infection. Antimicrob Resist Infect Control 2018;7:75. [PMID: 29946450 DOI: 10.1186/s13756-018-0365-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
79 Lopes Cançado GG, Silveira Silva RO, Rupnik M, Nader AP, Starling de Carvalho J, Miana de Mattos Paixão G, Martins Resende BA, Faria Lobato FC, Vilela EG. Clinical epidemiology of Clostridium difficile infection among hospitalized patients with antibiotic-associated diarrhea in a university hospital of Brazil. Anaerobe 2018;54:65-71. [DOI: 10.1016/j.anaerobe.2018.08.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
80 Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, du Toit B, Fredericks ES, Lekalakala-Mokaba MR, Maluleka C, Rajabally MN, Reubenson G, Shuping L, Swart K, Swe Han KS, Wadula J, Wojno J, Lowman W. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis 2020;35:219. [PMID: 34485483 DOI: 10.4102/sajid.v35i1.219] [Reference Citation Analysis]
81 Wijarnpreecha K, Sornprom S, Thongprayoon C, Phatharacharukul P, Cheungpasitporn W, Nakkala K. The risk of Clostridium difficile associated diarrhea in nasogastric tube insertion: A systematic review and meta-analysis. Digestive and Liver Disease 2016;48:468-72. [DOI: 10.1016/j.dld.2016.01.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
82 Oh SH, Kang HY. Identification of target risk groups for population-based Clostridium difficile infection prevention strategies using a population attributable risk approach. Int J Infect Dis 2018;66:107-12. [PMID: 29162405 DOI: 10.1016/j.ijid.2017.11.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
83 Blanco N, O'Hara LM, Robinson GL, Brown J, Heil E, Brown CH, Stump BD, Sigler BW, Belani A, Miller HL, Chiplinski AN, Perlmutter R, Wilson L, Morgan DJ, Leekha S. Health care worker perceptions toward computerized clinical decision support tools for Clostridium difficile infection reduction: A qualitative study at 2 hospitals. Am J Infect Control 2018;46:1160-6. [PMID: 29803592 DOI: 10.1016/j.ajic.2018.04.204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
84 Gil F, Calderón IL, Fuentes JA, Paredes-Sabja D. Clostridioides (Clostridium) difficile infection: current and alternative therapeutic strategies. Future Microbiol 2018;13:469-82. [PMID: 29464969 DOI: 10.2217/fmb-2017-0203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Yang S, Rider BB, Baehr A, Ducoffe AR, Hu DJ. Racial and ethnic disparities in health care-associated Clostridium difficile infections in the United States: State of the science. Am J Infect Control 2016;44:91-6. [PMID: 26454749 DOI: 10.1016/j.ajic.2015.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
86 Khattab RA, Ahmed NA, Ragab YM, Rasmy SA. Bacteria producing antimicrobials against Clostridium difficile isolated from human stool. Anaerobe 2020;63:102206. [PMID: 32339663 DOI: 10.1016/j.anaerobe.2020.102206] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Pizarro-Guajardo M, Ravanal MC, Paez MD, Callegari E, Paredes-Sabja D. Identification of Clostridium difficile Immunoreactive Spore Proteins of the Epidemic Strain R20291. Proteomics Clin Appl 2018;12:e1700182. [PMID: 29573213 DOI: 10.1002/prca.201700182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
88 Beinortas T, Burr NE, Wilcox MH, Subramanian V. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. The Lancet Infectious Diseases 2018;18:1035-44. [DOI: 10.1016/s1473-3099(18)30285-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
89 Bradshaw C, Zheng Y, Silver SA, Chertow GM, Long J, Anand S. Acute Kidney Injury Due to Diarrheal Illness Requiring Hospitalization: Data from the National Inpatient Sample. J Gen Intern Med 2018;33:1520-7. [PMID: 29916026 DOI: 10.1007/s11606-018-4531-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
90 Litao G, Jingjing S, Yu L, Lei Z, Xiaona H, Zhijing Z. Risk Factors for Antibiotic-Associated Diarrhea in Critically Ill Patients. Med Sci Monit. 2018;24:5000-5007. [PMID: 30020891 DOI: 10.12659/msm.911308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
91 Bradley ES, Howe E, Wu X, Haran JP. Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment. Gut Pathog 2019;11:29. [PMID: 31210787 DOI: 10.1186/s13099-019-0309-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
92 Muñoz M, Ríos-Chaparro DI, Herrera G, Soto-De Leon SC, Birchenall C, Pinilla D, Pardo-Oviedo JM, Josa DF, Patarroyo MA, Ramírez JD. New Insights into Clostridium difficile (CD) Infection in Latin America: Novel Description of Toxigenic Profiles of Diarrhea-Associated to CD in Bogotá, Colombia. Front Microbiol 2018;9:74. [PMID: 29441053 DOI: 10.3389/fmicb.2018.00074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
93 Berry AC, Learned M, Garland J, Berry L, Rodriguez S, Scott B, Berry BB. Intensive Care Unit Probiotic Utilization Rates: When Committee Recommendations and Physician Utilization Diverge. Infect Control Hosp Epidemiol 2017;38:1011-3. [PMID: 28592341 DOI: 10.1017/ice.2017.117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
94 Meng X, Huang X, Peng Z, Wang Y, Liu S, Zeng C, Duan J, Wen X, Fu C, Wu A, Li C. Antibiotic Resistances and Molecular Characteristics of Clostridioides difficile in ICUs in a Teaching Hospital From Central South China. Front Med (Lausanne) 2021;8:745383. [PMID: 34938744 DOI: 10.3389/fmed.2021.745383] [Reference Citation Analysis]
95 Wagner JL, Stover KR, Bell AM, Barber KE. Risk factors for development of initial Clostridioides difficile infection. J Glob Antimicrob Resist 2021;25:18-22. [PMID: 33667706 DOI: 10.1016/j.jgar.2021.02.012] [Reference Citation Analysis]
96 Hinc K, Kabała M, Iwanicki A, Martirosian G, Negri A, Obuchowski M. Complete genome sequence of the newly discovered temperate Clostridioides difficile bacteriophage phiCDKH01 of the family Siphoviridae. Arch Virol 2021;166:2305-10. [PMID: 34014385 DOI: 10.1007/s00705-021-05092-0] [Reference Citation Analysis]
97 Lübbert C, Zimmermann L, Borchert J, Hörner B, Mutters R, Rodloff AC. Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis. Infect Dis Ther 2016;5:545-54. [PMID: 27770261 DOI: 10.1007/s40121-016-0135-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
98 Furukawa K, Mitsutake H, Aso R, Sekizawa R, Okanda T, Hayashi K, Matsumoto T, Nakamura S. Usefulness of a newly developed high-speed polymerase chain reaction analysis system for the diagnosis of Clostridioides difficile infection. J Infect Chemother 2021;27:715-21. [PMID: 33402305 DOI: 10.1016/j.jiac.2020.12.020] [Reference Citation Analysis]
99 Worth LJ, Spelman T, Bull AL, Brett JA, Richards MJ. Epidemiology of Clostridium difficile infections in Australia: enhanced surveillance to evaluate time trends and severity of illness in Victoria, 2010-2014. J Hosp Infect 2016;93:280-5. [PMID: 27107622 DOI: 10.1016/j.jhin.2016.03.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
100 Muñoz-Miralles J, Trindade BC, Castro-Córdova P, Bergin IL, Kirk LA, Gil F, Aronoff DM, Paredes-Sabja D. Indomethacin increases severity of Clostridium difficile infection in mouse model. Future Microbiol 2018;13:1271-81. [PMID: 30238771 DOI: 10.2217/fmb-2017-0311] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
101 Zhang Y, Sun J, Zhang J, Liu Y, Guo L. Enzyme Inhibitor Antibiotics and Antibiotic-Associated Diarrhea in Critically Ill Patients. Med Sci Monit. 2018;24:8781-8788. [PMID: 30512009 DOI: 10.12659/msm.913739] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Xiao Y, Paquet-bolduc B, Garenc C, Gervais P, Trottier S, Roussy J, Longtin J, Loo VG, Longtin Y. Impact of Isolating Clostridium difficile Carriers on the Burden of Isolation Precautions: A Time Series Analysis. Clinical Infectious Diseases 2018;66:1377-82. [DOI: 10.1093/cid/cix1024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
103 Stoesser N, Eyre DW, Quan TP, Godwin H, Pill G, Mbuvi E, Vaughan A, Griffiths D, Martin J, Fawley W, Dingle KE, Oakley S, Wanelik K, Finney JM, Kachrimanidou M, Moore CE, Gorbach S, Riley TV, Crook DW, Peto TEA, Wilcox MH, Walker AS; Modernising Medical Microbiology Informatics Group (MMMIG). Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains. PLoS One 2017;12:e0182307. [PMID: 28813461 DOI: 10.1371/journal.pone.0182307] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 9.4] [Reference Citation Analysis]
104 Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Oneto C, Feuerstadt P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes 2020;4:14. [PMID: 32076853 DOI: 10.1186/s41687-020-0179-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
105 Castro-Córdova P, Díaz-Yáñez F, Muñoz-Miralles J, Gil F, Paredes-Sabja D. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence. Anaerobe 2020;62:102149. [PMID: 31940467 DOI: 10.1016/j.anaerobe.2020.102149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
106 Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents 2016;48:1-10. [PMID: 27216385 DOI: 10.1016/j.ijantimicag.2016.03.008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
107 Zhu D, Sorg JA, Sun X. Clostridioides difficile Biology: Sporulation, Germination, and Corresponding Therapies for C. difficile Infection. Front Cell Infect Microbiol 2018;8:29. [PMID: 29473021 DOI: 10.3389/fcimb.2018.00029] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
108 Kong LY, Eyre DW, Corbeil J, Raymond F, Walker AS, Wilcox MH, Crook DW, Michaud S, Toye B, Frost E, Dendukuri N, Schiller I, Bourgault AM, Dascal A, Oughton M, Longtin Y, Poirier L, Brassard P, Turgeon N, Gilca R, Loo VG. Clostridium difficile: Investigating Transmission Patterns Between Infected and Colonized Patients Using Whole Genome Sequencing. Clin Infect Dis 2019;68:204-9. [PMID: 29846557 DOI: 10.1093/cid/ciy457] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
109 Silva-velazco J, Hull TL, Messick C, Church JM. Medical versus Surgical Patients with Clostridium difficile Infection: Is There Any Difference? The American Surgeon 2016;82:1155-9. [DOI: 10.1177/000313481608201219] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
110 Vaid S, Park JS, Sinnott RJ. Outcomes of Recurrent Rectal Cancer after Transanal Excision. The American Surgeon 2016;82:152-5. [DOI: 10.1177/000313481608200219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 Hamo Z, Azrad M, Fichtman B, Peretz A. The Cytopathic Effect of Different Toxin Concentrations From Different Clostridioides difficile Sequence Types Strains in Vero Cells. Front Microbiol 2021;12:763129. [PMID: 34712220 DOI: 10.3389/fmicb.2021.763129] [Reference Citation Analysis]
112 Li BY, Oh J, Young VB, Rao K, Wiens J. Using Machine Learning and the Electronic Health Record to Predict Complicated Clostridium difficile Infection. Open Forum Infect Dis 2019;6:ofz186. [PMID: 31139672 DOI: 10.1093/ofid/ofz186] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
113 Xu X, Luo Y, Song X, Ying J, Ye J, Lu Y, Cai J, Ma J, Wang X, Yu W, Wang Y, Jin D. Evaluation of an UltraFast LabChip V280 assay for detection of toxigenic Clostridium difficile. Diagn Microbiol Infect Dis 2018;92:279-83. [PMID: 30029809 DOI: 10.1016/j.diagmicrobio.2018.06.021] [Reference Citation Analysis]
114 Suarez-Carantoña C, Rodriguez-Torres A, Viteri-Noel A, Pintado V, Garcia-Fernandez S, Mora-Pimentel D, Escudero-Sanchez R, Martin-Jusdado F, Moreno S, Cobo J. Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile. J Clin Med 2021;10:1627. [PMID: 33921309 DOI: 10.3390/jcm10081627] [Reference Citation Analysis]
115 Evans CT, Fitzpatrick M, Ramanathan S, Kralovic SM, Burns SP, Goldstein B, Smith B, Gerding DN, Johnson S. Healthcare facility-onset, healthcare facility-associated Clostridioides difficile infection in Veterans with spinal cord injury and disorder. J Spinal Cord Med 2020;43:642-52. [PMID: 31663843 DOI: 10.1080/10790268.2019.1672953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Dinh A, Le Monnier A, Emery C, Alami S, Torreton É, Duburcq A, Barbier F. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study. Eur J Clin Microbiol Infect Dis 2019;38:1297-305. [PMID: 30941532 DOI: 10.1007/s10096-019-03552-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
117 Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095. [PMID: 29257353 DOI: 10.1002/14651858.cd006095.pub4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 90] [Article Influence: 15.6] [Reference Citation Analysis]
118 Džunková M, D'Auria G, Xu H, Huang J, Duan Y, Moya A, Kelly CP, Chen X. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection. Front Cell Infect Microbiol 2016;6:119. [PMID: 27757389 DOI: 10.3389/fcimb.2016.00119] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
119 Viswesh V, Hincapie AL, Yu M, Khatchatourian L, Nowak MA. Development of a bedside scoring system for predicting a first recurrence of Clostridium difficile-associated diarrhea. Am J Health Syst Pharm 2017;74:474-82. [PMID: 28336757 DOI: 10.2146/ajhp160186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
120 Kleinman L, Talbot GH, Hunsche E, Schüler R, Nord CE. The CDI-DaySyms: Content Development of a New Patient-Reported Outcome Questionnaire for Symptoms of Clostridium difficile Infection. Value in Health 2018;21:441-8. [DOI: 10.1016/j.jval.2017.08.3017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Barber GE, Hendler S, Okafor P, Limsui D, Limketkai BN. Rising Incidence of Intestinal Infections in Inflammatory Bowel Disease: A Nationwide Analysis. Inflammatory Bowel Diseases 2018;24:1849-56. [DOI: 10.1093/ibd/izy086] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
122 Mohammed Abdul MK, Bhandari S. Change in the Mortality Trend of Hospitalized Patients with Clostridium difficile Infection: A Nation-wide Study. Cureus 2020;12:e6759. [PMID: 32140327 DOI: 10.7759/cureus.6759] [Reference Citation Analysis]
123 Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology 2017;153:430-438.e2. [DOI: 10.1053/j.gastro.2017.04.044] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 10.4] [Reference Citation Analysis]
124 Goldstein EJC, Johnson SJ, Maziade PJ, Evans CT, Sniffen JC, Millette M, McFarland LV. Probiotics and prevention of Clostridium difficile infection. Anaerobe 2017;45:114-9. [PMID: 27988389 DOI: 10.1016/j.anaerobe.2016.12.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
125 Gil F, Lagos-moraga S, Calderón-romero P, Pizarro-guajardo M, Paredes-sabja D. Updates on Clostridium difficile spore biology. Anaerobe 2017;45:3-9. [DOI: 10.1016/j.anaerobe.2017.02.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
126 Turner NA, Anderson DJ. Hospital Infection Control: Clostridioides difficile. Clin Colon Rectal Surg 2020;33:98-108. [PMID: 32104163 DOI: 10.1055/s-0040-1701234] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Romero-Rodríguez A, Troncoso-Cotal S, Guerrero-Araya E, Paredes-Sabja D. The Clostridioides difficile Cysteine-Rich Exosporium Morphogenetic Protein, CdeC, Exhibits Self-Assembly Properties That Lead to Organized Inclusion Bodies in Escherichia coli. mSphere 2020;5:e01065-20. [PMID: 33208520 DOI: 10.1128/mSphere.01065-20] [Reference Citation Analysis]
128 McFarland LV, Ship N, Auclair J, Millette M. Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence. J Hosp Infect 2018;99:443-52. [PMID: 29702133 DOI: 10.1016/j.jhin.2018.04.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
129 Zhang K, Zhao S, Wang Y, Zhu X, Shen H, Chen Y, Sun X. The non-toxigenic Clostridium difficile CD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain. Anaerobe 2015;36:49-52. [PMID: 26461425 DOI: 10.1016/j.anaerobe.2015.09.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
130 Plaza-Garrido Á, Barra-Carrasco J, Macias JH, Carman R, Fawley WN, Wilcox MH, Hernández-Rocha C, Guzmán-Durán AM, Alvarez-Lobos M, Paredes-Sabja D. Predominance of Clostridium difficile ribotypes 012, 027 and 046 in a university hospital in Chile, 2012. Epidemiol Infect 2016;144:976-9. [PMID: 26489717 DOI: 10.1017/S0950268815002459] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
131 Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger L, Wenzler E. Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile. Ann Clin Microbiol Antimicrob 2017;16:77. [PMID: 29202797 DOI: 10.1186/s12941-017-0252-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
132 McFarland LV. Therapies on the horizon for Clostridium difficile infections. Expert Opin Investig Drugs 2016;25:541-55. [PMID: 26934513 DOI: 10.1517/13543784.2016.1161025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
133 Wombwell E, Chittum ME, Leeser KR. Inpatient Proton Pump Inhibitor Administration and Hospital-Acquired Clostridium difficile Infection: Evidence and Possible Mechanism. The American Journal of Medicine 2018;131:244-9. [DOI: 10.1016/j.amjmed.2017.10.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
134 Hostler CJ, Bertumen JB, Park LP, Wilkins SB, Woods CW. Differences in time-to-testing and time-to-isolation between community-onset and hospital-onset Clostridioides difficile cases at a tertiary care VA medical center. Am J Infect Control 2020;48:1148-51. [PMID: 31911067 DOI: 10.1016/j.ajic.2019.12.008] [Reference Citation Analysis]
135 Plaza-Garrido Á, Miranda-Cárdenas C, Castro-Córdova P, Olguín-Araneda V, Cofré-Araneda G, Hernández-Rocha C, Carman R, Ibáñez P, Fawley WN, Wilcox MH, Gil F, Calderón IL, Fuentes JA, Guzmán-Durán AM, Alvarez-Lobos M, Paredes-Sabja D. Outcome of relapsing Clostridium difficile infections do not correlate with virulence-, spore- and vegetative cell-associated phenotypes. Anaerobe 2015;36:30-8. [PMID: 26403333 DOI: 10.1016/j.anaerobe.2015.09.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
136 Soavelomandroso AP, Gaudin F, Hoys S, Nicolas V, Vedantam G, Janoir C, Bouttier S. Biofilm Structures in a Mono-Associated Mouse Model of Clostridium difficile Infection. Front Microbiol 2017;8:2086. [PMID: 29118745 DOI: 10.3389/fmicb.2017.02086] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
137 Ge IY, Fevrier HB, Conell C, Kheraj MN, Flint AC, Smith DS, Herrinton LJ. Reducing risk of Clostridium difficile infection and overall use of antibiotic in the outpatient treatment of urinary tract infection. Ther Adv Urol 2018;10:283-93. [PMID: 30186366 DOI: 10.1177/1756287218783871] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
138 Cataldo MA, Granata G, Petrosillo N. Clostridium difficile infection: new approaches to prevention, non-antimicrobial treatment, and stewardship. Expert Rev Anti Infect Ther 2017;15:1027-40. [PMID: 28980505 DOI: 10.1080/14787210.2017.1387535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
139 McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol 2016; 22(11): 3078-3104 [PMID: 27003987 DOI: 10.3748/wjg.v22.i11.3078] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 51] [Article Influence: 11.2] [Reference Citation Analysis]
140 Sumon ZE, Lesse AJ, Sellick JA, Tetewsky S, Mergenhagen KA. Temporal trends of inpatient C. difficile infections within the Veterans Health Administration hospitals: An analysis of the effect of molecular testing, time to testing, and mandatory reporting. Infect Control Hosp Epidemiol 2020;41:44-51. [PMID: 31708000 DOI: 10.1017/ice.2019.281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017;152:1889-1900.e9. [PMID: 28192108 DOI: 10.1053/j.gastro.2017.02.003] [Cited by in Crossref: 137] [Cited by in F6Publishing: 106] [Article Influence: 27.4] [Reference Citation Analysis]
142 Pizarro-guajardo M, Chamorro-veloso N, Vidal RM, Paredes-sabja D. New insights for vaccine development against Clostridium difficile infections. Anaerobe 2019;58:73-9. [DOI: 10.1016/j.anaerobe.2019.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
143 Marttila-Vaara M, Ylipalosaari P, Kauma H. Clostridium difficile infections in teaching hospital in northern Finland. BMC Infect Dis 2019;19:48. [PMID: 30634939 DOI: 10.1186/s12879-018-3663-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Legenza LM, Barnett SG, Rose WE. Vaccines in development for the primary prevention of Clostridium difficile infection. J Am Pharm Assoc (2003) 2017;57:547-9. [PMID: 28712463 DOI: 10.1016/j.japh.2017.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
145 Mora Pinzon MC, Buie R, Liou J, Shirley DK, Evans CT, Ramanathan S, Poggensee L, Safdar N. Outcomes of Community and Healthcare-onset Clostridium difficile Infections. Clinical Infectious Diseases 2019;68:1343-50. [DOI: 10.1093/cid/ciy715] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
146 Cotter KJ, Fan Y, Sieger GK, Weight CJ, Konety BR. Prevalence of Clostridium Difficile Infection in Patients After Radical Cystectomy and Neoadjuvant Chemotherapy. Bladder Cancer 2017;3:305-10. [PMID: 29152554 DOI: 10.3233/BLC-170132] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
147 Ramírez-Vargas G, López-Ureña D, Badilla A, Orozco-Aguilar J, Murillo T, Rojas P, Riedel T, Overmann J, González G, Chaves-Olarte E, Quesada-Gómez C, Rodríguez C. Novel Clade C-I Clostridium difficile strains escape diagnostic tests, differ in pathogenicity potential and carry toxins on extrachromosomal elements. Sci Rep 2018;8:13951. [PMID: 30224751 DOI: 10.1038/s41598-018-32390-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
148 Agarwal M, Dick AW, Sorbero M, Mody L, Stone PW. Changes in US Nursing Home Infection Prevention and Control Programs From 2014 to 2018. J Am Med Dir Assoc 2020;21:97-103. [PMID: 31888867 DOI: 10.1016/j.jamda.2019.10.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
149 Brito-Silva C, Pizarro-Cerda J, Gil F, Paredes-Sabja D. Identification of Escherichia coli strains for the heterologous overexpression of soluble Clostridium difficile exosporium proteins. J Microbiol Methods 2018;154:46-51. [PMID: 30291882 DOI: 10.1016/j.mimet.2018.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]